Business of BioTechniques
December update In December, the Business of BioTechniques blog highlights industry collaborations designed to advance novel SARS-CoV-2 drug discovery and development, alongside company acquisitions to enhance research data management and lab efficiency. Also, in the drug discovery space, financing news outlines company progress in the RNA therapeutics field and growth and expansion of service capabilities and clinical trial advancement. Industry developments in SARS-CoV-2 & COVID-19 The Native Antigen Company’s SARS-CoV-2 Neutralization Assay Development Kits are selected as The Scientist 2021 Top 10 Innovation The Native Antigen Company, part of LGC Clinical Diagnostics and one of the world’s leading suppliers of...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!
